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Aims Despite the lower patency of venous compared with arterial coronary artery bypass grafts, 50%
of grafts used are saphenous vein conduits because of their easier accessibility. In a search for ways to
increase venous graft patency, we applied the results of a previous pharmacological study screening
for non-toxic compounds that inhibit intimal hyperplasia of saphenous vein conduits in organ cultures.
Here we analyse the effects and mechanism of action of leoligin [(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-
(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl (2Z)-2-methylbut-2-enoat, the major lignan from
Edelweiss (Leontopodium alpinum Cass.).
Methods and results We found that leoligin potently inhibits vascular smooth muscle cell (SMC) prolifer-
ation by inducing cell cycle arrest in the G1-phase. Leoligin induced cell death neither in SMCs nor, more
importantly, in endothelial cells. In a human saphenous vein organ culture model for graft disease, leo-
ligin potently inhibited intimal hyperplasia, and even reversed graft disease in pre-damaged vessels.
Furthermore, in an in vivo mouse model for venous bypass graft disease, leoligin potently inhibited
intimal hyperplasia.
Conclusion Our data suggest that leoligin might represent a novel non-toxic, non-thrombogenic, endo-







Coronary artery bypass grafting (CABG) and percutaneous
coronary intervention (PCI) are the two invasive options to
treat coronary artery disease (CAD), one of the leading
causes of morbidity and mortality worldwide.
1 The success
of these approaches is, however, often limited by restenosis
and graft failure. With respect to graft patency rates after
CABG, the vessels of choice are clearly the internal
mammary arteries.
2 However, these arteries have limited
availability; hence, saphenous vein grafts are more
frequently used in CABG than arterial grafts (e.g. in 2004
at our institution, saphenous veins were used in 51% of
bypass grafts
3). Clinical optimization like graft handling
(e.g. ‘no touch techniques’) and aggressive lipid-lowering
therapy has impressively increased the patency rates of
saphenous vein conduits; the current rates are 60% 10
years after CABG.
3–5 The major reasons for a loss of
patency at earlier time points are thromboses, neointima
formation, and intimal hyperplasia, with 10–20% loss of
patency occurring after the ﬁrst year; loss at later periods
are due to development of graft atherosclerosis.
4,6,7
The causative factors and the pathophysiological pro-
cesses that underlie vein graft disease are not well under-
stood. It is thought that vein graft disease is the result of †These authors contributed equally to this work.
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surgical handling, ischaemia, or arterialization (blood
pressure and blood ﬂow) of the grafts. This initial damage
is thought to provoke adaptive repair processes in the
vessel wall, like tissue remodelling (positive and negative)
and intimal hyperplasia.
4,6–8 While this response is vital for
the adaptation of the graft to the arterial environment,
excessive response is believed to give rise to graft disease
that ultimately results in graft failure.
Despite a complex array of intra- and inter-cellular signal-
ling events in the development of graft disease after CABG
and/or PCI, the core elements at the histological level are
endothelial damage (denudation), and smooth muscle cell
(SMC) proliferation and inﬁltration of the intima.
Pro-inﬂammatory signalling, due to tissue damage and cellu-
lar necrosis and also as an element of adaptive tissue remo-
delling, is another highly relevant factor.
9 Although the use
of drug-eluting stents/matrices instead of purely mechan-
ical devices will be the most likely approaches in PCI- and
CABG-based prevention of restenosis and graft failure,
there is a lack of drugs, screened or designed precisely for
these applications. Currently used drugs are mainly agents
developed for cancer or immunosuppressive therapy, which
may be too aggressive or unspeciﬁc for the treatment of
restenosis and graft disease; furthermore, endothelial
healing, important for the prevention of thromboses, is
also impaired by these drugs.
Keeping these issues in mind, we previously screened a set
of compounds in an organ culture model for their ability to
inhibit intimal hyperplasia in human saphenous veins
in vitro. The concept underlying our screen was that the
compounds of interest must inhibit intimal hyperplasia and
neointima formation in saphenous vein organ cultures,
without being toxic for endothelial cells (ECs).
2. Methods
2.1 General
All reagents used were of analytical grade quality and were pur-
chased from Sigma Aldrich (Vienna, Austria) if not speciﬁed other-
wise. Water was produced by reverse osmosis followed by
distillation.
2.2 Study design
We had previously screened a set of plant extracts and compounds
as candidate drugs for the treatment and prevention of cardiovascu-
lar diseases in a CABG setting. The initial screening was performed
in organ cultures of human saphenous vein conduits (see below).
The grafts were incubated with various plant extracts (for a list,
see ref. 10), selected on the basis of their anti-inﬂammatory and
anti-proliferative activity, as well as with six compounds and iso-
lates with similar activities, such as histone deacetylase inhibitors
(butyric acid and trichostatin A), curcumin, two bisabolane-type
compounds, and leoligin. Of all extracts and compounds tested, leo-
ligin proved to be the most efﬁcient in inhibiting intimal hyperplasia
of grafts without exerting any toxic effects and was therefore
analysed further to elucidate its mechanisms of action as well as
its in vivo applicability. A proliferation-inhibiting activity of leoligin
in the absence of cell death induction was demonstrated both in
SMCs and ECs (Figures 3 and 5). Furthermore, we examined the
cell cycle-modulating activity of leoligin, and its effects on inhibi-
tors of the cell cycle. Within the limits of the study, leoligin had
no major side effects, since it exhibited no pro-thrombotic, cell
death-inducing or protein synthesis-inhibiting activities.
2.3 Plant material, isolation, and puriﬁcation of
leoligin
Leoligin was re-isolated according to the procedure as described.
11
The sub-aerial plant parts (5.30 kg) used for isolation were obtained
from cultures. A voucher specimen (CH 5002) has been deposited at
the herbarium of the Institute of Pharmacy/Pharmacognosy, Univer-
sity of Innsbruck. Purity of leoligin according to LC-DAD/MS- and
NMR examination was .98%.
2.4 Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated from
umbilical cords (kindly donated by the Gynaecology and Obstetrics
Department, Innsbruck Medical University) by enzymatic detachment
using collagenase, as described previously.
12 Human umbilical vein
SMCs were isolated from the same umbilical cords.
13 SMCs were rou-
tinely passaged in 0.2% gelatine-coated (Sigma, Steinheim, Germany)
polysterene culture ﬂasks (Becton–Dickinson, Meylan Cedex, France)
in Medium 231 (Cascade Biologics, Paisley, UK). The isolation and
analysis of human umbilical cord ECs and SMCs has been approved
by the Ethics Committee of the Innsbruck Medical University.
2.5 Quantiﬁcation of cell death and cellular DNA
content
For detection and/or quantiﬁcation of cell death, forward/sideward
light scattering analysis, the AnnexinV/propidium iodide method,
and staining of nuclear DNA content (cell cycle analyses) were
used as described in.
14
2.6 Analysis of cellular proliferation
Cell proliferation was measured by the XTT cell proliferation assay
(Biomol, Hamburg, Germany) as described by the manufacturer.
2.7 Surface expression analyses of ICAM-1, VCAM-1
and E-selectin
FACS-based analyses of surface adhesion molecule expression were
performed according to a protocol by Grabner et al.,
15 using
anti-VCAM-1 antibody (clone 1.4 C3; Neomarkers), anti-ICAM-1 anti-
body (clone 28; DAKO Cytomation), and anti-E-selectin antibody
(clone 16G4; Novo castra).
2.8 Western blotting
Western blotting was performed as described previously,
16 with the
primary antibodies anti-p27/KIP-1 antibody (clone 57; BD Transduc-
tion Laboratories).
2.9 Metabolic labelling of proteins
Metabolic labelling with 35S-methionine/cysteine was performed as
described previously.
16 Brieﬂy, cells were treated as indicated for
16 h. After washing the cells three times with labelling medium
(nine parts of methionine-free RPMI 1640 þ one part RPMI 1640 þ
10% FCS), cells were incubated for 8 h with labelling medium con-
taining 75 mCi/mL of 35S-methionine/cysteine mix (Hartmann
Radiochemicals, Germany) in the presence or absence of leoligin.
Thereafter, cells were washed twice with cold PBS and lysed
(150 mM NaCl, 0.1% Triton X-100, 30 mM Tris, 1 mM PMSF, 10% gly-
cerol, and peptide inhibitors). After protein preparation, total cel-
lular proteins were separated on polyacrylamide gels, and the dried
gels were analysed by exposure to X-ray ﬁlms.
2.10 Human saphenous vein organ culture
For organ culture experiments, remnants (surgical waste) of saphe-
nous veins from patients undergoing CABG were collected. The
saphenous veins were opened longitudinally and attached to silicone
Leoligin inhibits bypass intimal hyperplasia 543patches (with the endothelium facing upwards). Tissue pieces were
incubated with culture medium (RPMI 1640, 30% serum, heparin
8 mU/mL, antibiotics) for 2 weeks to induce intimal hyperplasia
(for details, see ref. 17). To test for a potential intimal
hyperplasia-inhibitory activity of leoligin, different concentrations
of leoligin, or DMSO as a solvent control, were added to the cultures
during the incubation period. The medium containing leoligin or
DMSO was replaced by fresh medium every second day. Baseline
samples were ﬁxed directly after preparation of fresh tissue and
represent the status of the vessel prior to organ culture. The use
of human saphenous veins has been approved by the Ethics Commit-
tee of the Innsbruck Medical University and conforms to the prin-
ciples of the Declaration of Helsinki.
2.11 Mouse model: vein graft disease
In the mouse model used, the vena cava of a donor mouse was inter-
posed into the carotid artery of a recipient mouse. After transplan-
tation and prior to wound closure, a 100 mL depot of 0.9% NaCl
(control group) or 100 mM leoligin in 0.9% NaCl (leoligin group)
was placed around the adventitia of the vein graft. Four weeks
after the intervention, mice were sacriﬁced and the interposed
venae cavae were harvested for analyses. Of the 14 animals in the
control group and 12 in the leoligin group which survived the surgi-
cal procedure, four control and two leoligin-treated animals showed
no blood ﬂow due to thromboses and were excluded from further
analyses. For details on the surgical procedure, see refs 17 and
18. In all experiments, male C57/BL6 mice were used. Animal
experiments were approved by the Commission for Animal Testing
of the Austrian Ministry for Science and Research.
2.12 Immunohistochemistry and morphometric
analyses
Following ﬁxation in 4% paraformaldehyde and dehydration of
tissues from organ culture or in vivo experiments, tissues were
embedded in parafﬁn (venae cavae from the in vivo experiments
were embedded into mouse liver prior to ﬁxation) and sections
were prepared. Immunohistochemistry was performed with the
Accustain Elastica Stain (HT25) kit (Sigma-Aldrich, USA) or the En
Visionþ System-HRP (DAB) (DakoCytomation, Denmark) according
to the manufacturers’ instructions. Primary antibodies used were
anti-p27/KIP-1 antibody (clone 57; BD Transduction Laboratories)
and anti-CD31/PECAM-1 antibody (clone JC70A; DakoCytomation).
The images were analysed by blinded researchers using the Image
J software of the National Institutes of Health (USA).
2.13 Statistics
Values for neointima thickness were statistically analysed using
Microsoft Excel and SPSS 11.0 software. Values of individual
groups were tested for a Gaussian distribution (Kolmogorov–Smir-
nov’s test) and equality of variances (Levene’s test). Further ana-
lyses were performed using ANOVA/Bonferroni adjustment
(Figure 2) followed by individual t-test comparisons of the groups
(Figures 2 and 6).
2.14 Platelet function test
Platelet function was assessed in vitro with the PFA-100
w test
system according to the manufacturer’s instructions (Siemens
healthcare Diagnostics, Eschborn, Germany).
19,20 Five whole blood
aliquots of two healthy volunteers with no reported medication
were drawn into 3.8 mL buffered citrate (0.129 mol/L, pH 5.5)
blood collection systems (S-Monovette for PFA 100, Sarstedt,
Nu ¨rnberg, Germany). One sample was used as blank. One other
sample was spiked with 3.8 mL DMSO prior to blood collection to
serve as carrier control. The other three samples were spiked
with 3.8 mL of one of three leoligin stock solutions (0.5, 5, and
50 mM, respectively). Both available PFA-100
w sub-tests have been
performed; i.e. platelet activators ADP (CADP) and epinephrine
(CEPI).
3. Results
3.1 Leoligin, a compound from Edelweiss, potently
inhibits intimal hyperplasia in a human saphenous




(Figure 1), a compound that was previously isolated from
the roots of Edelweiss (Leontopodium alpinum Cass.), is a
lignan-type secondary plant metabolite. In an organ
culture model for screening agents capable of inhibiting
human saphenous vein intimal hyperplasia, leoligin showed
a profound inhibitory activity (Figure 2). Leoligin potently
inhibited intimal hyperplasia in a dose-dependent manner
when added freshly every second day to organ cultures
over a period of 2 weeks. Five micromolar leoligin comple-
tely inhibited intimal hyperplasia (P ¼ 0.003), and 50 mM
even reversed pre-existing intimal hyperplasia of saphenous
veins (P , 0.001) (Figure 2). Intimal thickness was assessed
by over 25 measurements per sample, and a total of ﬁve
samples (different donors) per concentration were analysed.
All image analyses and quantiﬁcations were performed by
blinded observers.
3.2 Leoligin inhibits smooth muscle cell
proliferation by inducing cell cycle arrest in the
G1-phase associated with accumulation and shift in
molecular weight of p27/KIP protein
In order to understand the mechanism underlying leoligin-
mediated inhibition and reversal of saphenous vein intimal
hyperplasia, we analysed the effects of leoligin on isolated
primary human vascular SMCs, which represent the central
Figure 1 Leoligin is a constituent of Edelweiss (Leontopodium alpinum
Cass.) roots. The popular alpine plant Edelweiss is used in folk medicine for
the treatment of indigestion, fever, and ‘abdominal aches’. Leoligin (IUPAC
name: [(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetra-
hydrofuran-3-yl]methyl (2Z)-2-methylbut-2-enoat) is a lignan, which we iso-
lated from the roots of Edelweiss.
U. Reisinger et al. 544cell type in intimal thickening and intimal hyperplasia (SMC
proliferation and migration). Our analyses clearly showed
that leoligin causes only a marginal increase in cell death
(apoptosis and necrosis) in SMCs after 48 h (Figure 3, right
panel). In contrast, analyses of cell numbers by the XTT
proliferation assay (Figure 3, left panel) as well as by Casy-
based cell counting (data not shown) revealed a signiﬁcant
SMC proliferation inhibitory effect of leoligin. Subsequent
measurements of nuclear DNA content (Figure 4, two
upper panels) revealed that leoligin causes a massive
Figure 3 Leoligin inhibits the proliferation of smooth muscle cells (SMCs) without causing cell death. In order to investigate the effect of leoligin on the cellular
level, isolated primary human vascular SMCs were incubated with the indicated concentrations of leoligin or solvent control (DMSO) for the indicated times. The
right diagram shows a FACS analysis of cell viability determined by annexin V/propidium iodide staining. Values are means of a representative experiment per-
formed in triplicate. The experiment was repeated three times, with similar results. The left diagram shows a cell proliferation analysis by the XTTassay. Values
are means of three independent experiments+SD.
Figure 2 Leoligin inhibits intimal hyperplasia of human saphenous veins in vitro. Upper left diagram summarizes the data from experiments where human
saphenous veins were induced to develop intimal hyperplasia in organ culture. Tissue samples were incubated with DMSO (solvent control) or various concen-
trations of leoligin for 2 weeks. Shown are mean values of intimal thickness (in pixel)+SD. Over 25 measurements per sample were carried out, and a total
of ﬁve samples (different donors) per concentration were analysed. All image analyses and quantiﬁcation were performed by blinded observers. **P , 0.01;
***P , 0.001. The images (control, leoligin 5 mM, and leoligin 50 mM) show the effect of the presence of leoligin on organ culture-caused intimal thickening
of a representative sample of a saphenous vein with mild pre-existing intimal hyperplasia (see image: baseline). The area between the arrows indicates the
intimal thickness. Representative images are shown.
Leoligin inhibits bypass intimal hyperplasia 545accumulation of cells in the G1-phase of the cell cycle.
Consequently, we performed western blot analysis of G1
arrest-relevant cell cycle regulators. The lower panel of
Figure 4 shows a western blot demonstrating that leoligin
induces a complete change in the appearance of p27/KIP
protein, i.e. from one signal at 27 kDa to an intensive
signal at 58 kDa, and three weak signals at 24, 27 (original
signal) and 85 kDa (the 85 kDa signal was hardly visible and
is not shown). All experiments were repeated at least
three times. Cell cycle and the western blot analyses were
repeated three times, and the results of representative
experiments are shown.
3.3 Leoligin is not toxic for endothelial cells and
inhibits TNF-a-mediated VCAM-1 expression
Since the integrity of the vascular endothelium plays a
central role in vascular repair and healing, anti-thrombosis,
and the graft atherosclerosis-relevant control of cell
(macrophages) and compound (cholesterol) exchange
between the blood and the vessel wall, we also analysed
the effects of leoligin on the vascular endothelium. Leoligin
inhibited the proliferation of ECs (Figure 5, upper right
panel) without having any or only a low degree of toxic or
cell death-inducing effects on them (Figure 5, upper left
panel). Interestingly, leoligin inhibited TNF-a-mediated
surface expression of VCAM-1 (Figure 5, lower left
panel).
21 To show that this is not due to a general phenom-
enon like inhibition of the endothelial translational machin-
ery by leoligin, we performed metabolic protein labelling
experiments (Figure 5, lower right panel) and analysed the
effect of leoligin on other adhesion molecules (Figure 5,
lower left panel). These data demonstrate that leoligin
does not block protein synthesis and does not interfere
with the translocation of proteins to the cell surface in
general, but speciﬁcally inhibits stimulated VCAM-1
expression on the EC surface. All experiments were
repeated at least three times, and the results of representa-
tive experiments are depicted.
3.4 Leoligin inhibits in vivo neointima formation
without causing endothelial damage
To test the feasibility of applying leoligin in vivo, we ana-
lysed the effects of leoligin in a mouse model for vein
graft disease (see Section 2). As in human saphenous vein
bypass conduits, the transplant develops severe intimal
hyperplasia within a couple of weeks.
Leoligin was applied after the transplantation directly as a
periadventitial reservoir (100 mL of 100 mM leoligin in 0.9%
NaCl) before surgical wound closure. Four weeks after trans-
plantation, mice were sacriﬁced and the venous conduits
were removed for further analyses. Thrombosed veins
were excluded from further analyses and the remaining
samples were subjected to immunohistochemical analysis.
Figure 6 (left side) shows that leoligin treatment, in contrast
to control treatment (0.9% NaCl), potently inhibited intimal
hyperplasia in vivo. Vein grafts of mice treated with leoligin
showed signiﬁcantly reduced neointimal thickness (upper
central and upper right image). A CD31 (endothelial
marker) staining of the sections revealed that the endo-
thelial layer of leoligin- and control-treated conduits was
intact. Finally, a p27/KIP staining of the sections revealed
that a large number of cells/nuclei in the leoligin-treated
grafts stained positive for p27/KIP even 4 weeks after appli-
cation of leoligin, indicating a long duration of drug effect.
The treatment groups included 14 animals in the control
group and 12 animals in the leoligin group. Four animals of
the control group and two animals of the leoligin group
were excluded from further analysis due to the presence
of thrombosis in the grafts. Immunohistochemistry has
been performed on samples from all animal; representative
images are shown.
3.5 Leoligin is not thrombogenic and does not
modulate normal platelet function
To examine potential pro-thrombotic activities of leoligin,
we performed a standard platelet function test by the
PFA-100
w test system (see Section 2). No signiﬁcant
changes in the aperture closure time by leoligin (0.5, 5,
and 50 mM) could be observed (data not shown). The test
was performed in triplicates from blood samples of two vol-
unteers with no reported medication.
4. Discussion
The popular alpine plant Edelweiss (L. alpinum Cass.) is used
in folk medicine for the treatment of diarrhoea, fever, and
‘abdominal pain’. Edelweiss root extracts show a complex
pattern of secondary plant metabolites of several compound
classes like coumarins, lignans, sesquiterpenes, polyacety-
lens, diterpenes, and others.
22 One of the major constitu-
ents of the roots is leoligin, a lariciresinol-type lignan.
Lignans are polyphenolic plant metabolites derived from
Figure 4 Leoligin induces a cell cycle arrest in the G1-phase and leads to
accumulation of p27/KIP. The histograms show the results from a DNA
content analysis of control-treated or leoligin-treated smooth muscle cells
(SMCs) after 24 h of incubation (upper left histogram: solvent control;
upper right histogram: leoligin 100 mM). The experiment was performed in
duplicates and repeated three times. A representative experiment is
shown. The lower panel shows a western blot analysis of p27/KIP of SMCs
incubated for 24 h with the indicated concentrations of leoligin. The exper-
iment was repeated three times, and a representative blot is shown.
U. Reisinger et al. 546phenylalanine via dimerization of substituted cinnamic
alcohols.
Until now, only a small number of studies have reported
on the impact of lignans on the cardiovascular system, and
only a few different lignans have been tested so far. The
existing data suggest that lignans have a preventive effect
on cardiovascular disease and are cell-protective agents
with lipid-lowering, anti-oxidative, anti-hypertensive,
anti-thrombotic, and anti-inﬂammatory activities;
however, a large number of lignan-based cancer therapy
studies (in vitro and in vivo) also have suggested a profound
cytotoxic and cell death-inducing activity of this class of
compounds.
23,24 In line with this, also profound anti-
angiogenic activity of certain lignans was demonstrated.
25,26
Currently available data are not free of contradictions,
which may be partially explained by the use of different
lignans and cell types. Honokiol, for instance, a lignan con-
stituent of the plant Magnolia ofﬁcinalis, was shown to
inhibit cell death in ECs,
27 but also to potentiate cell
death in vivo and in vitro in other systems.
28 In SMCs, hono-
kiol was demonstrated to induce an arrest in the G1-phase of
the cell cycle, which is associated with up-regulation of
p21/WAF1.
29 Magnolol, another lignan isolated from
M. ofﬁcinalis, induces cell death in SMCs in a caspase-
dependent manner;
30 it inhibited both TNF-a-mediated
VCAM-1 expression,
31 and IL-6-induced STAT3 expression in
ECs.
32 An interesting study by Razuvaev et al.
33 reported
that the cyclolignan picropodophyllin inhibited intimal
hyperplasia in vivo after balloon injury via interaction with
the IGF-receptor and ERK signalling pathway. A few other
lignan-type compounds, like ﬂax seed lignans, have been
tested in different model systems of inﬂammation, cancer,
and cardiovascular diseases.
In general, however, due to a lack of knowledge concern-
ing the speciﬁcities and characteristics of lignans, the mech-
anisms underlying the interaction of lignans with cells and
organ systems, like the cardiovascular system, have not
been well deﬁned.
In contrast to previously analysed lignans, the present
study demonstrated that leoligin is not toxic for SMCs and
ECs. This may be due to the structural differences
between individual lignans. Leoligin may represent a
special type of lignan characterized by its cell cycle inhibi-
tory activity and importantly also by its lack of toxicity
and cell death-inducing activity. In contrast to honokiol,
which causes a cell cycle arrest in the G1-phase by
up-regulating p21/WAF1,
29 our data suggest that leoligin
causes a G1 arrest by increasing p27/KIP protein levels.
Although the effect of both compounds is similar namely, a
G1-phase arrest, the underlying signalling processes may
Figure 5 Leoligin is non-toxic for ECs and inhibits TNF-a-mediated VCAM-1 expression. Primary human vascular endothelial cells (ECs) were incubated with the
indicated concentrations of leoligin for the indicated times. The upper left diagram shows a representative analysis of cell viability determined by the annexin V/
propidium iodide staining and FACS analyses. Values are means of a representative experiment performed in triplicate. The upper right diagram shows EC pro-
liferation as determined by the XTTassay. Values are means of three independent experiments+SD. The impact of leoligin on TNF-a-induced surface expression
of VCAM-1, ICAM-1, and E-selectin (E-Sel) is shown in the lower left diagram. Data shown are mean ﬂuorescence intensities (MFI), % of control, of a representative
experiment. The experiment was repeated three times. The lower right image shows a metabolic protein labelling of ECs in the presence of the indicated con-
centrations of leoligin. The experiment was repeated three times, giving similar results. A representative blot is shown.
Leoligin inhibits bypass intimal hyperplasia 547differ. P27/KIP is well known to bind and thereby inactivate
the cyclinE/cdk2 complex which phosphorylates pRB. Phos-
phorylated pRB loses its ability to inhibit transcription
factors like E2F, which upon release, activates proliferation-
promoting genes. The shift in the molecular weight of p27/
KIP-1 at 50 mM leoligin from 27 to 58 kDa and 85 kDa may
indicate the binding of p27/KIP-1 to the cyclinE/cdk2
complex or may also indicate an oligomerization of mol-
ecules (dimers/trimers). The above in vitro results were
supported by our in vivo experiments, where leoligin was
applied as a periadventitial reservoir to vein graft after
the re-implantation. Immunohistochemistry of tissue
samples taken 4 weeks after the treatment showed still a
large number of SMCs in the leoligin group staining positive
for p27/KIP. This may indicate that the mechanisms
described above are active also in vivo and that a single
dose of leoligin exerts a long-lasting effect in vivo.
However, the precise signalling pathways activated by leoli-
gin leading to the accumulation and change in the molecular
weight of p27/KIP-1 protein remain to be elucidated.
To overcome or delay vein graft failure after CABG, the
major therapeutic aims are the prevention of neointima for-
mation and intimal hyperplasia as well as graft atherosclero-
sis. Although some progress has been made in past years,
suitable drugs are still lacking. With improved understanding
of the cellular and molecular mechanisms leading to vein
graft failure after CABG, several treatment strategies
emerged for inhibiting or blocking neointima formation
and intimal hyperplasia as well as graft atherosclerosis.
Numerous drugs like heparins, angiotensin-converting
enzyme inhibitors, antagonists to growth factors such as ter-
binaﬁne or trapidil, angiopeptin (a peptide analogue of
somatostatin), and cytostatic agents such as etoposide or
doxorubicin have been tested for their capability to
prevent vascular proliferative diseases. However, the efﬁ-
cacy documented in animal studies could not be achieved
in clinical trials.
34 At present, anti-proliferative thera-
peutics targeting speciﬁc parts of the cell cycle are in the
focus of interest. Promising agents include rapamycine, a
macrocyclic triene antibiotic produced by Streptomyxes
hygroscopius, paclitaxel, a cytotoxic bark constitutent of
Taxus brevifolia, and ﬂavopiridol, a semi-synthetic ﬂavone
derivative.
Leoligin is an interesting alternative. In contrast to most
of these compounds, some of which are also clinically
applied, leoligin is not toxic for ECs. Cytotoxic agents are
too aggressive and often cause not only SMC apoptosis and
inhibition of proliferation, but also signiﬁcantly reduced
endothelial viability. Since vascular endothelial wound
closure after PCI or CABG is very important in vascular
healing and anti-thrombosis, compounds that are less toxic
for ECs are interesting agents for the prevention of graft
failure and might play an important role in intra- and extra-
vascular drug-eluting stents and matrices. Leoligin seems to
Figure 6 Leoligin inhibits neointima formation in vivo without causing endothelial damage. The left diagram displays a morphometric analysis of intimal thick-
ness of vena cava interposed into the carotid artery of control-treated and leoligin-treated animals. Mean values of groups (mm)+SD are shown. Group size was
10 animals in the control group and 10 animals in the leoligin group. Right side: upper two images show Elastica van Giesson staining of sections of the venous
conduits. White arrows indicate neointimal thickness which was analysed by morphometry (left diagram). Central images display a staining with the endothelial
cell CD31/PECAM-1 antigen (brown, black arrows) combined with a haematoxylin stain. Lower images display immunohistochemical staining of the sections with
the cell cycle inhibitor p27/KIP-1 (brown) combined with a haematoxylin stain. Lu, lumen; Li, liver. All image analyses and quantiﬁcation were performed by
blinded observers. In all images shown, results of a representative experiment are depicted. Immunohistochemistry was performed on samples from all animals.
U. Reisinger et al. 548possess precisely this characteristic. Although it inhibits ECs
proliferation (Figure 5), which may reduce local endothelial
healing, a wound repair via the circulation (EC precursors
and circulating ECs) seems possible. Accordingly, leoligin
seems to be a promising compound to treat and prevent
intimal hyperplasia and thromboses after CABG.
Without doubt, additional studies are required to eluci-
date the applicability of leoligin in a clinical setting.
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